PLRZ
Polyrizon Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$11.13
−2.46%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$11.29
From 52W high−35.21%
Volume3740.00
Market cap$27.02M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$11.29
From 52W high
−35.21%
Volume
3740.00
Market cap
$27.02M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
P/E (TTM)
—
RSI (14)
59.5
MomentumView details →
1D Return
−2.46%
YTD Return
+29.74%
SummaryUpdated Jun 1, 2026
Polyrizon Ltd. (NASDAQ:PLRZ) is an Israeli biotechnology company founded in 2005 and headquartered in Ra'anana, Israel. The company went public on October 29, 2024, making it one of the newest entrants to the public markets in the biotech sector. Polyrizon specializes in developing innovative medical device hydrogels delivered through nasal spray formulations designed to create protective barriers against viruses and allergens. As a pre-revenue biotech company, Polyrizon is currently in the development phase of its product pipeline, focusing on respiratory protection and allergy management solutions.
Similar companies
Latest newsMore news →
Polyrizon Ltd. announced that enrollment and randomization were complete for all 120 planned participants in its U.S. multicenter clinical study of NASARIX.8d agoPolyrizon filed a U.S. patent application to expand intellectual property protection around its intranasal drug-delivery platform.30d agoPolyrizon enrolled the first patient in a U.S. clinical study evaluating the efficacy, safety and tolerability of its NASARIX (PL-14) Allergy Blocker in patients with seasonal allergic rhinitis.43d ago